Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC)
Related Posts
Mishra A, Huang SB, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa[...]
Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, Bitman E, Thant W, Liu T, Weipert C, Fell G, Spring LM, Wander[...]
Zong Y, Huang R, Bitar M, Drakaki A, Zhang L, Lin DI, Ye H. Molecular diversity of embryonic-type neuroectodermal tumors arising from testicular germ cell[...]